PYPD
PolyPid Ltd. NASDAQ$4.50
Mkt Cap $45.9M
52w Low $2.44
76.9% of range
52w High $5.12
50d MA $4.37
200d MA $3.95
P/E (TTM)
-2.1x
EV/EBITDA
-2.1x
P/B
6.6x
Debt/Equity
0.2x
ROE
-311.4%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
1.46
50d MA
$4.37
200d MA
$3.95
Avg Volume
52.4K
About
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | AMC | -0.34 | -0.41 | -20.6% | 4.62 | -0.4% | -0.6% | -4.1% | -4.5% | -8.0% | -7.6% | — |
| Nov 12, 2025 | AMC | -0.54 | -0.37 | +31.5% | 3.75 | +0.0% | -4.5% | -4.3% | -2.9% | -2.9% | -4.0% | — |
| Aug 13, 2025 | AMC | -0.53 | -0.78 | -47.2% | 3.49 | +0.3% | -1.7% | -1.1% | +0.6% | +1.1% | +0.3% | — |
| May 14, 2025 | AMC | -0.80 | -0.70 | +12.5% | 2.90 | +1.4% | -1.7% | -5.2% | -3.1% | +0.0% | -3.1% | — |
| Feb 12, 2025 | AMC | -0.90 | -1.13 | -25.6% | 2.97 | +0.3% | -4.7% | -0.7% | -3.4% | -2.4% | +1.0% | — |
| Nov 13, 2024 | AMC | -1.07 | -1.22 | -14.0% | 3.40 | +0.6% | +0.6% | +4.4% | +1.8% | +5.9% | +2.6% | — |
| Aug 14, 2024 | AMC | -1.51 | -1.25 | +17.2% | 3.49 | -2.6% | +3.2% | +7.4% | +1.7% | +2.6% | +1.1% | — |
| May 8, 2024 | AMC | -1.96 | -1.37 | +30.1% | 4.31 | +4.4% | +4.4% | +10.0% | +10.0% | +0.9% | +10.0% | — |
| Feb 14, 2024 | AMC | -2.17 | -3.97 | -82.9% | 6.23 | +1.8% | +1.3% | +2.7% | -15.7% | -14.3% | -12.2% | — |
| Nov 8, 2023 | AMC | -3.62 | -3.40 | +6.1% | 4.18 | +0.5% | -7.7% | -10.3% | -3.6% | -3.8% | -6.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.68 | $4.58 | -2.1% | -1.3% | -1.9% | -5.3% | -5.8% | -9.2% |
| Nov 13 | Roth Capital | Maintains | Buy → Buy | — | $3.75 | $3.75 | +0.0% | -4.5% | -4.3% | -2.9% | -2.9% | -4.0% |
| Aug 14 | Craig-Hallum | Maintains | Buy → Buy | — | $3.49 | $3.50 | +0.3% | -1.7% | -1.1% | +0.6% | +1.1% | +0.3% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.42 | $3.38 | -1.2% | +2.0% | +0.3% | +0.9% | +2.6% | +3.2% |
| Jun 18 | Roth Capital | Maintains | Buy → Buy | — | $3.53 | $3.52 | -0.3% | -6.2% | -7.1% | +4.2% | +1.4% | +5.9% |
| Jun 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.67 | $3.57 | -2.7% | -3.8% | -9.8% | -10.6% | +0.3% | -2.5% |
| Jun 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.27 | $3.79 | +15.9% | +2.8% | +7.0% | +5.8% | +4.9% | +4.3% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.48 | $2.57 | +3.6% | +2.8% | +8.9% | +10.9% | +10.5% | +10.9% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.97 | $2.83 | -4.7% | -4.0% | -2.7% | +6.1% | +2.4% | +2.7% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.62 | +0.4% | -6.9% | -4.2% | +10.0% | +34.1% | +23.4% |
Data updated apr 26, 2026 9:22pm
· Source: massive.com